Related Experiment Video
Updated: Aug 6, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor
Naga Praneeth Raja1,2, Nagapavani Kandagari3
1Division of Hematology and Oncology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, 97239, Portland, OR , USA. nagapraneeth21d@gmail.com.
Abstract:
Rectal gastrointestinal stromal tumors (GISTs) represent approximately 5-8.5% of all GISTs and pose unique surgical challenges due to the confined pelvic anatomy and proximity to the anal sphincter complex. Historically, radical surgery - including abdominoperineal resection (APR) or pelvic exenteration - was frequently required for complete tumor clearance, resulting in permanent colostomy and significant functional morbidity. The introduction of imatinib mesylate, a selective tyrosine kinase inhibitor (TKI) targeting KIT and PDGFRA, has fundamentally transformed the management of rectal GIST. Neoadjuvant imatinib therapy achieves significant tumor downsizing (25-46% reduction), reduces mitotic activity, and enables sphincter-preserving surgery in patients who would otherwise require radical resection. The concurrent evolution of transanal endoscopic platforms - including transanal endoscopic microsurgery (TEM), transanal minimally invasive surgery (TAMIS), and robotic TAMIS (R-TAMIS) - has further expanded the possibilities for organ preservation, achieving R0 resection rates of 89-100% with favorable functional outcomes and preserved fecal continence. Emerging evidence also suggests improvements in distant recurrence-free survival, disease-specific survival, and overall survival compared with upfront surgery. This comprehensive narrative review examines the rationale, efficacy, response assessment, surgical implications, the role of transanal surgical platforms, functional outcomes, quality of life, survival outcomes, and current guideline recommendations for neoadjuvant imatinib in rectal GIST.
Insights
Neoadjuvant imatinib therapy significantly shrinks rectal gastrointestinal stromal tumors (GISTs), enabling sphincter-preserving surgery. This approach improves outcomes and reduces the need for radical resections and permanent colostomies.
Area of Science:
- Gastroenterology and Surgical Oncology
- Pharmacological Treatment of Neoplasms
- Minimally Invasive Surgical Techniques
Background:
- Rectal gastrointestinal stromal tumors (GISTs) present surgical challenges due to pelvic anatomy.
- Historically, radical surgery with high morbidity was often necessary.
- Imatinib mesylate has revolutionized rectal GIST management.
Purpose of the Study:
- To review the efficacy and implications of neoadjuvant imatinib in rectal GIST.
- To explore the role of transanal endoscopic platforms in organ preservation.
- To summarize current recommendations for neoadjuvant imatinib therapy.
Main Methods:
- Comprehensive narrative review of existing literature.
- Analysis of studies on neoadjuvant imatinib efficacy and response.
- Evaluation of transanal surgical techniques (TEM, TAMIS, R-TAMIS) for rectal GIST.
Main Results:
- Neoadjuvant imatinib causes significant tumor downsizing (25-46%) and reduces mitotic activity.
- Transanal endoscopic platforms achieve high R0 resection rates (89-100%) with preserved function.
- Improved survival outcomes and reduced functional morbidity are suggested compared to upfront surgery.
Conclusions:
- Neoadjuvant imatinib is effective for rectal GIST, facilitating sphincter-preserving surgery.
- Transanal minimally invasive surgery enhances organ preservation and functional outcomes.
- This combined approach offers a promising alternative to historical radical resections.
